Partners HealthCare and Illumina Announce Founding Members of GeneInsight Network

  Partners HealthCare and Illumina Announce Founding Members of GeneInsight
  Network

    Providing Medical Geneticists and Pathologists with Infrastructure and
Networking Tools to Support the Clinical Interpretation and Reporting Process

Business Wire

BOSTON & SAN DIEGO -- January 7, 2013

Partners HealthCare and Illumina, Inc. (NASDAQ:ILMN) today announced the
GeneInsight-Illumina Founding Network Members, including the ARUP
Laboratories, Mount Sinai Genetic Testing Laboratory, New York Genome Center
(NYGC), Partners HealthCare, and Illumina. The members represent a diverse and
distinguished group of laboratories within leading academic institutions and
commercial organizations who are interested in leveraging clinical-grade
genomics interpretation and reporting. The members are committed to exploring
and sharing knowledge, including variant level content and interpretations,
through the formation of inter-laboratory collaborations and “knowledge
rings.” The network will be opened widely later in 2013 to other institutions
willing to share clinical genomic data.

“Today’s announcement reinforces our commitment to establishing a
community-based approach to addressing some of the most challenging issues
related to clinical next-generation sequencing,” said Heidi Rehm, PhD, Chief
Laboratory Director, Partners’ Laboratory for Molecular Medicine. “We’re
excited to bring together such a talented and diverse group of leading
institutions who share a common vision and are passionate about the
opportunities for collaboration to advance the field of clinical genetics.”

Elaine Lyon, PhD, Medical Director, ARUP Laboratories echoes this sentiment
and expressed her enthusiasm for a community approach to curating variant
knowledge saying, “As a user of the GeneInsight application, I look forward to
participating in a network of leading genetic testing laboratories and
academic institutions to curate genetic variants. This collaborative effort
can greatly contribute to improving patient care.”

The founding members are serving as initial pilot sites for the deployment and
implementation of a combined offering that integrates the functionality of
Illumina’s MiSeq® sequencing system and Partners GeneInsight Suite®, an IT
platform that streamlines the analysis, interpretation, and reporting of
complex genetic test results. As pilot sites, the members have a unique
opportunity to represent the community of clinical lab professionals,
geneticists and genetic counselors to improve upon the combined
GeneInsight-Illumina offering and to prepare it for general release. They also
will be instrumental in developing a resource that has the potential to add to
the effectiveness of genetic testing.

Another founding member, the New York Genome Center, is an independent,
non-profit organization leveraging the collaborative resources of leading
academic medical centers, research universities, and commercial organizations
to create one of the largest genomics research facilities in North America. As
an enterprise focused squarely on fostering a collaborative environment, it
believes its involvement in the network will help drive the translation of
basic research into clinical care.

“The New York Genome Center has brought together leading research, clinical,
and technology collaborators in an effort to transform science and
healthcare,” said Nancy J. Kelley, NYGC Founding Executive Director. “Partners
HealthCare and Illumina share our vision for innovation through collaboration,
so we are privileged to be a Founding Member of the GeneInsight-Illumina
Network. We look forward to using these new tools with other members of the
network to promote discovery and improve patient care.”

In September 2012, Partners HealthCare and Illumina announced their strategic
alliance and shared commitment to bringing a broader community of clinical
laboratories together to expand and enrich collective knowledge about genetics
with the goal of improving patient care.

“Today’s announcement represents a significant milestone toward achieving
GeneInsight and Illumina’s shared vision of enabling the market to apply
sequencing technology to improve human health. Illumina is excited to be among
such reputable founding members and is committed to using GeneInsight in our
CLIA-certified, CAP accredited laboratory to support the growing demand for
our Understand Your Genome Symposia,” said Matt Posard, Senior Vice President
and General Manager of Illumina’s Translational and Consumer business.

About Partners HealthCare

Partners HealthCare is a Boston-based integrated health system founded by
Brigham and Women’s Hospital and Massachusetts General Hospital that also
includes community and specialty hospitals, community health centers, a
physician network, and home health and long-term care services. Further
information can be found by visiting www.partners.org.

About GeneInsight, LLC

GeneInsight LLC (www.geneinsight.com) is a wholly-owned subsidiary of Partners
HealthCare. GeneInsight Suite® was developed by Partners HealthCare in
collaboration with leading geneticists, laboratory operations personnel,
practicing physicians and IT professionals. GeneInsight has been in clinical
use since 2005 and has supported the interpretation and reporting workflow for
more than 25,000 complex genetic tests across multiple diagnostic reference
laboratories, including Partners HealthCare Laboratory for Molecular Medicine.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130107006829/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50523721&lang=en

Contact:

Partners HealthCare
Media:
Rich Copp, 617-278-1031
Rcopp@partners.org
or
Illumina, Inc.
Investors:
Rebecca Chamber, 858-255-5243
Investor Relations
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
Public Relations
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.